SCHEMBL30775199

SCHEMBL30775199

CCN(C)c1ccnc(OC2CCNC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.44
CHRM1 P11229 2/20 0.40
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
PRKCZ Q05513 1/20 0.39
ACACB O00763 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM3 P20309 1/20 0.35
ROCK1 Q13464 3/20 0.35
ROCK2 O75116 2/20 0.35
KCNH2 Q12809 1/20 0.35
PRKCI P41743 2/20 0.34
CHUK O15111 1/20 0.34
DYRK3 O43781 1/20 0.34
MAP4K4 O95819 1/20 0.34
PIM1 P11309 1/20 0.34
PRKACA P17612 1/20 0.34
RPS6KB1 P23443 1/20 0.34
AKT1 P31749 1/20 0.34
CLK2 P49760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775269 0.87 CHRNB2 (0.43) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL4800992 0.79 IRAK4 (0.46) IRAK4PRKCZROCK1ROCK2CHUK
SCHEMBL29003837 0.77 CHRNB2 (0.46) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL29003833 0.77 CHRNB2 (0.46) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30422988 0.77 CHRNB2 (0.46) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775337 0.74 IRAK4 (0.45) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775298 0.73 CHRM1 (0.43) CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL30775429 0.73 IRAK4 (0.55) IRAK4CHRNB2CHRNA4PRKCZCHUK
SCHEMBL7889387 0.71 CHRNB2 (0.54) IRAK4CHRM1CHRNB2CHRNA4PRKCZ
SCHEMBL4102786 0.71 CHRNB2 (0.54) IRAK4CHRM1CHRNB2CHRNA4PRKCZ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR IRAK4 4638/4885CHRM1 4823/4885CHRNB2 3816/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR IRAK4 4638/4885CHRM1 4823/4885CHRNB2 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.